Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U; Central European Society for Anticancer Drug Research-EWIV. Lentz F, et al. Among authors: dittrich c. Anticancer Drugs. 2009 Feb;20(2):97-103. doi: 10.1097/CAD.0b013e328322fbc5. Anticancer Drugs. 2009. PMID: 19209025 Clinical Trial.
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
Hofheinz RD, Dittrich C, Jakupec MA, Drescher A, Jaehde U, Gneist M, Graf von Keyserlingk N, Keppler BK, Hochhaus A. Hofheinz RD, et al. Among authors: dittrich c. Int J Clin Pharmacol Ther. 2005 Dec;43(12):590-1. doi: 10.5414/cpp43590. Int J Clin Pharmacol Ther. 2005. PMID: 16372529 Clinical Trial. No abstract available.
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME. Mross K, et al. Among authors: dittrich c. Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14. Br J Cancer. 2012. PMID: 22699824 Free PMC article. Clinical Trial.
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L. Chan S, et al. Among authors: dittrich c. J Clin Oncol. 2005 Aug 10;23(23):5314-22. doi: 10.1200/JCO.2005.66.130. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955899 Clinical Trial.
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M. Steinbild S, et al. Among authors: dittrich c. Br J Cancer. 2007 Dec 3;97(11):1480-5. doi: 10.1038/sj.bjc.6604064. Epub 2007 Nov 27. Br J Cancer. 2007. PMID: 18040273 Free PMC article. Clinical Trial.
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A. Schmidt M, et al. Among authors: dittrich c. Ann Oncol. 2010 Feb;21(2):275-282. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24. Ann Oncol. 2010. PMID: 19633042 Free article. Clinical Trial.
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH. van Kesteren C, et al. Among authors: dittrich c. Invest New Drugs. 2005 Jun;23(3):225-34. doi: 10.1007/s10637-005-6730-3. Invest New Drugs. 2005. PMID: 15868378
233 results